Navigation Links
Immunosuppressant further linked to birth defects
Date:2/6/2008

A new study documents malformations seen in an infant born to a kidney transplant recipient who had taken mycophenolate mofetil (MMF), a widely used immunosuppressant available commercially as Cellcept. The findings suggest a specific birth defect pattern particular to this drug, reinforcing its potential to harm to the fetus. The study was published in the January 2008 issue of the American Journal of Medical Genetics, available online via Wiley InterScience at http://www3.interscience.wiley.com/journal/117869018/issue.

Approximately 14,000 births to organ transplant recipients, primarily kidney transplant patients, have been reported worldwide. Although pregnancy was initially ill-advised for these women, the American Society of Transplantation concluded in 2003 that pregnancy is usually safe following the first year of a transplant, provided that organ rejection or other complications have not occurred. The fetal side-effects of several immunosuppressant drugs have been studied, though not for widely used newer medications, such as (MMF).

The use of immunosuppressant drugs is a required, life-long treatment for solid organ transplant recipients. They are used to prevent, inhibit or reduce the natural reaction of the immune system against foreign tissues. However, these drugs have important side effects that sometimes preclude their use. The FDA divides immunosuppressants into four categories (A, B, C and D) regarding toxicity to the fetus. MMF has recently been upgraded to class D during pregnancy, meaning that its use is precluded for the high risk of fetal malformations. Immunosupressants are also given to women with severe autoimmune diseases, such as generalized lupus. In fact, 3 out of 10 babies described in the literature regarding these defects had mothers on MMF because of lupus nephritis.

Led by Dr. Antonio Perez-Aytes and Dr. Maximo Vento of the New
'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Further development of Water Framework Directive necessary
2. Further breakthroughs for breast cancer patients
3. Worlds largest investor coalition seeks further disclosure on climate change and shareholder value
4. Risk of common vaginal infection linked to preterm birth appears higher for blacks
5. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
6. Protein chatter linked to cancer activation
7. Western diet linked to increased risk of colon cancer recurrence
8. Sugary drinks, not fruit juice, may be linked to insulin
9. Brains timing linked with timescales of the natural visual world
10. Low vitamin D during pregnancy linked to pre-eclampsia
11. Genetic variant linked to odor perception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... North Carolina State University researcher has shown that water-gel-based ... solar cells to produce electricity. The findings prove the ... nature. They also have the potential to be less ... silicon-based solar cells. The bendable devices are composed ...
... , This release is available in Spanish ... a popular native Hawaiian fruit, has been released by U.S. ... cooperators. ,Ōhelo ( Vaccinium reticulatum Smith ) is ... found at high elevations on the islands of Maui and ...
... an effective vaccine for malaria is a step closer following ... to infect human cells. The discovery, by researchers at The ... new vaccine target through which infection with the deadly disease ... people contract malaria, and more than one million, mostly children, ...
Cached Biology News:Mimicking nature, water-based 'artificial leaf' produces electricity 2Scientists release first cultivated ohelo berry for Hawaii 2Malaria's newest pathway into human cells identified 2
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)... , March 3, 2015 ... with tools for implementing competency-based training to comply with ... DirectCourse is offering a new crosswalk tool ... (HCBS) implement competency-based training for direct service workers as ... & Medicaid Services (CMS) regulations. CMS amended ...
(Date:3/3/2015)... Md. , March 3, 2015  Synthetic Biologics, Inc. ... infections and diseases, with a focus on protecting the microbiome, ... is scheduled to present at the 27th Annual ROTH Conference ... Laguna Niguel in Dana Point, ... Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time). ...
(Date:3/3/2015)... 3, 2015  PDL BioPharma, Inc. (PDL or the ... the third of three shareholder lawsuits filed in the ... On February 2, 2015, a securities lawsuit that ... of a putative class of purchasers of the Company,s ... 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed without prejudice.  Shortly ...
Breaking Biology Technology:Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2
... Quintiles,Transnational Corp. today announced the appointment of ... Troullis had been,acting CFO since former CFO John ... Troullis joined Quintiles in 1992 as Director ... CFO, Troullis was Senior Vice President and,Worldwide Controller. ...
... Offer Regulatory ... Operations Expertise, WHIPPANY, N.J., Aug. ... services to streamline the drug,development lifecycle, today announced the expansion of ... Diego. The announcements,illustrate the company,s newly elevated focus on emerging West ...
... at the 58th Annual Meeting of ... (AASLD), TAMPA, Fla., Aug. 15 Romark Laboratories ... of Alinia(R) (nitazoxanide) for,treating chronic hepatitis C in the ... evaluate the effectiveness and safety,of Alinia tablets administered in ...
Cached Biology Technology:ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 3ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 4Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 2Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 3Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 4
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
...
...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products: